| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
Atherosclerosis and Lipoproteins |
From the Wihuri Research Institute (R.O., P.T.K., P.L., M.O.P.) and the Department of Bacteriology and Immunology, University of Helsinki, and Helsinki University Central Hospital (H.J., S.M.) Helsinki, Finland.
Correspondence to Petri T. Kovanen, MD, Wihuri Research Institute, Kalliolinnantie 4, FIN-00140 Helsinki, Finland. E-mail petri.kovanen{at}wri.fi
Objective Complement activation has been suggested to play a role in atherogenesis. To study the regulation of complement activation in human coronary atherosclerotic lesions, we examined the spatial relationships between the major complement inhibitor, factor H, and the complement activation products C3d and C5b-9.
Methods and Results In early lesions (American Heart Association types II and III), factor H was immunohistochemically found in the superficial proteoglycan-rich layer in association with numerous macrophages and C3d, whereas C5b-9 was found deeper in the intima, where factor H was virtually absent. In vitro experiments involving surface plasmon resonance and affinity chromatography analyses demonstrated that isolated human arterial proteoglycans bind factor H, and functional complement assays showed that glycosaminoglycans inhibit the complement activation induced by modified low density lipoprotein or by a foreign surface.
Conclusions The present observations raise the possibility that proteoglycans, because of their ability to bind the major complement inhibitor factor H, may inhibit complement activation in the superficial layer of the arterial intima. In contrast, deeper in the intima, where factor H and proteoglycans are absent, complement may be activated and proceed to C5b-9. Thus, the superficial and the deep layers of the human coronary artery appear to differ in their ability to regulate complement activation.
Key Words: atherosclerosis complement factor H proteoglycans
This article has been cited by other articles:
![]() |
V. W.Y. Leung, S. Yun, M. Botto, J. C. Mason, T. H. Malik, W. Song, D. Paixao-Cavalcante, M. C. Pickering, J. J. Boyle, and D. O. Haskard Decay-Accelerating Factor Suppresses Complement C3 Activation and Retards Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice Am. J. Pathol., October 1, 2009; 175(4): 1757 - 1767. [Abstract] [Full Text] [PDF] |
||||
![]() |
K. C.M.C. Koeijvoets, S. P. Mooijaart, G. M. Dallinga-Thie, J. C. Defesche, E. W. Steyerberg, R. G.J. Westendorp, J. J.P. Kastelein, P. M. van Hagen, and E. J.G. Sijbrands Complement factor H Y402H decreases cardiovascular disease risk in patients with familial hypercholesterolaemia Eur. Heart J., March 1, 2009; 30(5): 618 - 623. [Abstract] [Full Text] [PDF] |
||||
![]() |
S. S. Boekhoorn, J. R. Vingerling, J. C. M. Witteman, A. Hofman, and P. T. V. M. de Jong C-reactive Protein Level and Risk of Aging Macula Disorder: The Rotterdam Study Arch Ophthalmol, October 1, 2007; 125(10): 1396 - 1401. [Abstract] [Full Text] [PDF] |
||||
![]() |
F. J. de Jong, M. K. Ikram, D. D. G. Despriet, A. G. Uitterlinden, A. Hofman, M. M. B. Breteler, and P. T. V. M. de Jong Complement Factor H Polymorphism, Inflammatory Mediators, and Retinal Vessel Diameters: The Rotterdam Study Invest. Ophthalmol. Vis. Sci., July 1, 2007; 48(7): 3014 - 3018. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. K. Pai, J. E. Manson, K. M. Rexrode, C. M. Albert, D. J. Hunter, and E. B. Rimm Complement factor H (Y402H) polymorphism and risk of coronary heart disease in US men and women Eur. Heart J., June 1, 2007; 28(11): 1297 - 1303. [Abstract] [Full Text] [PDF] |
||||
![]() |
V. K. Bhatia, S. Yun, V. Leung, D. C. Grimsditch, G. M. Benson, M. B. Botto, J. J. Boyle, and D. O. Haskard Complement C1q Reduces Early Atherosclerosis in Low-Density Lipoprotein Receptor-Deficient Mice Am. J. Pathol., January 1, 2007; 170(1): 416 - 426. [Abstract] [Full Text] [PDF] |
||||
![]() |
T. T. Keller, S. I. van Leuven, M. C. Meuwese, N. J. Wareham, R. Luben, E. S. Stroes, C. E. Hack, M. Levi, K.-T. Khaw, and S. M. Boekholdt Serum Levels of Mannose-Binding Lectin and the Risk of Future Coronary Artery Disease in Apparently Healthy Men and Women Arterioscler Thromb Vasc Biol, October 1, 2006; 26(10): 2345 - 2350. [Abstract] [Full Text] [PDF] |
||||
![]() |
I. Kardys, C. C.W. Klaver, D. D.G. Despriet, A. A.B. Bergen, A. G. Uitterlinden, A. Hofman, B. A. Oostra, C. M. Van Duijn, P. T.V.M. de Jong, and J. C.M. Witteman A Common Polymorphism in the Complement Factor H Gene Is Associated With Increased Risk of Myocardial Infarction: The Rotterdam Study J. Am. Coll. Cardiol., April 18, 2006; 47(8): 1568 - 1575. [Abstract] [Full Text] [PDF] |
||||
![]() |
R. Oksjoki, P. T. Kovanen, K. A. Lindstedt, B. Jansson, and M. O. Pentikainen OxLDL-IgG Immune Complexes Induce Survival of Human Monocytes Arterioscler Thromb Vasc Biol, March 1, 2006; 26(3): 576 - 583. [Abstract] [Full Text] [PDF] |
||||
![]() |
J. L. Haines, M. A. Hauser, S. Schmidt, W. K. Scott, L. M. Olson, P. Gallins, K. L. Spencer, S. Y. Kwan, M. Noureddine, J. R. Gilbert, et al. Complement Factor H Variant Increases the Risk of Age-Related Macular Degeneration Science, April 15, 2005; 308(5720): 419 - 421. [Abstract] [Full Text] [PDF] |
||||
![]() |
G. Camejo Hydrolytic Enzymes Released From Resident Macrophages and Located in the Intima Extracellular Matrix as Agents That Modify Retained Apolipoprotein B Lipoproteins Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1312 - 1313. [Full Text] [PDF] |
||||
![]() |
H. Rus and F. Niculescu Association of Complement Inhibitors With Connective Tissue Matrix in Atherosclerotic Lesions Arterioscler Thromb Vasc Biol, August 1, 2003; 23(8): 1478 - 1478. [Full Text] [PDF] |
||||
|
ATVB Home | Subscriptions | Archives | Feedback | Authors | Help | AHA Journals Home | Search Copyright © 2003 American Heart Association, Inc. All rights reserved. Unauthorized use prohibited. |